BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23904341)

  • 1. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
    Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
    Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.
    Boehmer G; Wang L; Iftner A; Holz B; Haedicke J; von Wasielewski R; Martus P; Iftner T
    BMC Infect Dis; 2014 Dec; 14():674. PubMed ID: 25487281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
    Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
    J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
    Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
    Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.
    Arbyn M; Buntinx F; Van Ranst M; Paraskevaidis E; Martin-Hirsch P; Dillner J
    J Natl Cancer Inst; 2004 Feb; 96(4):280-93. PubMed ID: 14970277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.
    Clavel C; Masure M; Levert M; Putaud I; Mangeonjean C; Lorenzato M; Nazeyrollas P; Gabriel R; Quereux C; Birembaut P
    Diagn Mol Pathol; 2000 Sep; 9(3):145-50. PubMed ID: 10976721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.
    Tuerxun G; Yukesaier A; Lu L; Aierken K; Mijiti P; Jiang Y; Abulizi A; Zhang Y; Abuduxikuer G; Abulizi G; Li H
    Oncologist; 2016 Jul; 21(7):825-31. PubMed ID: 27317575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens.
    Kapala J; Jang D; Patel J; Biers K; Smieja M; Chernesky M
    J Virol Methods; 2007 Jun; 142(1-2):223-5. PubMed ID: 17320978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme.
    Moss SM; Bailey A; Cubie H; Denton K; Sargent A; Muir P; Vipond IB; Winder R; Kitchener H
    Cytopathology; 2015 Dec; 26(6):373-80. PubMed ID: 25274541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.
    Belinson JL; Hu S; Niyazi M; Pretorius RG; Wang H; Wen C; Smith JS; Li J; Taddeo FJ; Burchette RJ; Qiao YL
    Int J Cancer; 2010 Sep; 127(5):1151-7. PubMed ID: 20039323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
    Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.
    Kurian EM; Caporelli ML; Baker S; Woda B; Cosar EF; Hutchinson L
    Am J Clin Pathol; 2011 Nov; 136(5):808-16. PubMed ID: 22031321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
    Kang WD; Kim CH; Cho MK; Kim JW; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2009 Jul; 19(5):924-8. PubMed ID: 19574786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
    Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
    J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.